20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Berlin Battery Lab: BAM, HZB and HU are conducting joint research on sodium batteriesThe Federal Institute for Materials Research and Testing (BAM), the Helmholtz Zentrum Berlin (HZB) and Humboldt-Universität zu Berlin (HU) today officially inaugurated the Berlin Battery Lab (BBL). At this new research platform, BAM, HZB and HU jointly develop and test resource-efficient battery technologies with a focus on sodium-based systems. Together, they develop new materials, investigate innovative cell chemistries, and produce battery prototypes. The research infrastructure of the Berlin Battery Lab is also open to external partners from science and industry and is designed to accelerate the transfer from research to application.
- Humboldt-Fellow at HZB Institute for Solar Fuels: Kayode Adesina AdegokeKayode Adesina Adegoke is a renowned chemist, affiliated with LAUTECH SDG 11 (Sustainable Cities and Communities Research Group), Department of Pure and Applied Chemistry, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. He is collaborating with Matthew Mayer to investigate the degradation of electrocatalysts during electrochemical CO₂ reduction. The Alexander von Humboldt Fellowship enables him to stay at Helmholtz Zentrum Berlin up to 24 months.
- Protein crystallography at BESSY II: faster, better and more and more automaticMany diseases are linked to malfunctions of proteins in the organism. The three-dimensional architecture of these molecules is often highly complex, but it can provide valuable insights into biological processes and the development of drugs. X-ray diffraction at the MX beamlines of BESSY II can be used to decipher the 3D structure of proteins. To date, more than 5000 structures have been solved at the three MX beamlines. Here, we present a review and an outlook with Manfred Weiss, head of the research group for macromolecular crystallography.